Foley Represents NEA as Lead Investor in Comanche Biopharma Series B Round

Foley & Lardner LLP recently represented New Enterprise Associates, Inc. (NEA) as lead investor in Comanche Biopharma Corp’s $75 million Series B financing. Existing investors GV (Google Ventures), F-Prime Capital, Lilly Asia Ventures (LAV), and Longview Healthcare Ventures also participated in the round, along with new investor Atlas Venture.

Comanche Biopharma is a maternal and fetal medicine biopharmaceutical company working to make every pregnancy around the world safer.  The company is currently developing the world’s first treatment for preeclampsia, which affects more than 10 million women globally every year. Their mission is to develop the first definitive treatment for sFlt1-mediated preterm preeclampsia and facilitate its availability globally.

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. Founded in 1977, NEA has over $25 billion in assets under management as of March 31, 2023, and invests in technology and health care companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm’s long track record of investing includes more than 270 portfolio company IPOs and more than 450 mergers and acquisitions.

The Foley team was led by partner Louis Lehot and included partners Antoinette Konski and Jeff Lomprey, senior counsel Alicia Dorner, and associates Saige Gallop and Trevor Mullin.